Next-Generation GPCR Heteromer Inhibitors and Therapeutic Platforms

A paradigm-shifting approach to GPCR heteromer-targeted therapies, integrating cutting-edge technologies like CRISPR-Cas9 gene editing, CAR-T cell therapy, and nano-particle delivery systems to create synergistic, personalized, and sustained therapeutic effects.

The original patent disclosed inhibitors of novel, functional GPCR heteromers, specifically targeting the CXCR4-HRH1 heteromer in cancer cells. However, these inhibitors have limitations in terms of efficacy, specificity, and delivery. The new inventive concept addresses these limitations by envisioning a next-generation approach that combines GPCR heteromer inhibitors with emerging technologies to create more effective, targeted, and sustained therapies.

The new inventive concept comprises a system integrating a GPCR heteromer inhibitor with a CRISPR-Cas9 gene editing tool, allowing for simultaneous targeting of the CXCR4-HRH1 heteromer and a gene associated with cancer progression. This synergy enables enhanced therapeutic effects. Additionally, the concept includes a method for treating cancer patients by combining a CXCR4-HRH1 heteromer-specific inhibitor with CAR-T cell therapy, enhancing the efficacy of the CAR-T cell therapy. Furthermore, a pharmaceutical composition featuring a CXCR4-HRH1 heteromer-specific inhibitor and a nano-particle delivery system provides sustained therapeutic effects. A diagnostic method for detecting CXCR4-HRH1 heteromers in biological samples and a system for personalized medicine, utilizing a GPCR heteromer profiling platform and CXCR4-HRH1 heteromer-specific inhibitors, complete the next-generation approach.

The new claims introduce a paradigm shift in GPCR heteromer-targeted therapies by integrating emerging technologies, such as CRISPR-Cas9 gene editing, CAR-T cell therapy, and nano-particle delivery systems, to create synergistic, personalized, and sustained therapeutic effects. This integration is new and non-obvious compared to the original patent, which focused solely on GPCR heteromer inhibitors.

Alternative embodiments may include using different gene editing tools, such as TALEN or ZFN, or combining GPCR heteromer inhibitors with other immunotherapies, like checkpoint inhibitors. Variations may involve targeting different GPCR heteromers or using different nano-particle delivery systems.

The next-generation GPCR heteromer inhibitors and therapeutic platforms have vast commercial potential in the oncology and immunotherapy markets, with potential applications in personalized medicine, cancer treatment, and gene therapy.